← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Bolder Biotechnology, Inc.
Boulder, CO
$29,978,397
Total funding
39
Grants
Funding over time
peak $3.2M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$29,978,397 · 39
By mechanism
R44$18,927,797 · 17
R43$5,046,911 · 20
N01$3,079,369 · 1
U01$2,924,320 · 1
Investigators at Bolder Biotechnology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"$1,650,819
N01 · FY2023 · AI
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"$1,428,550
N01 · FY2024 · AI
Long-Acting G-CSF Analog for Treating ARS$1,196,000
R44 · FY2015 · AI
Long-Acting G-CSF Analog for Treating ARS$1,000,000
R44 · FY2014 · AI
Long-Acting G-CSF Analog for Treating ARS$1,000,000
R44 · FY2013 · AI
Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn$1,000,000
R44 · FY2009 · AI
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation$1,000,000
R44 · FY2023 · AI
Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn$976,501
R44 · FY2008 · AI
Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing$826,535
R44 · FY2008 · NS
Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing$790,800
R44 · FY2009 · NS
Long-acting EPO analog for treating anemia associated with chronic kidney disease$767,785
R44 · FY2009 · DK
Long-acting growth factors for treating the acute and long term effects of lethal$731,319
U01 · FY2014 · AI
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation$717,432
R44 · FY2024 · AI
Long-acting growth factors for treating the acute and long term effects of lethal$674,036
U01 · FY2016 · AI
Long-acting growth factors for treating the acute and long term effects of lethal$553,403
U01 · FY2015 · AI
Long-acting growth factors for treating the acute and long term effects of lethal$488,794
U01 · FY2013 · AI
Long-acting growth factors for treating the acute and long term effects of lethal$476,768
U01 · FY2017 · AI
Long-acting EPO analog for treating anemia associated with chronic kidney disease$472,707
R44 · FY2010 · DK
Long-Acting IL-11 for Treating Thrombocytopenia$457,625
R44 · FY2003 · CA
Long Acting VEGF BInding Proteins for Treating Cancer$440,699
R44 · FY2006 · CA